Periorbitale Kontaktekzeme

Zusammenfassung

Periorbitale Kontaktekzeme sind am häufigsten Folge einer allergischen Kontaktdermatitis, während andere ekzematöse Erkrankungen wie das atopische Ekzem oder das seborrhoische Ekzem seltener auftreten. Differenzialdiagnostisch müssen auch Autoimmunerkrankungen sowie die Rosazea in Betracht gezogen werden. Die allergische Kontaktdermatitis ist eine T-Zell-vermittelte immunologische Antwort auf ubiquitär vorkommende Kontaktstoffe. Über das Endothel wandern aktivierte T-Zellen in die Haut und produzieren Entzündungsmediatoren. Wichtigster diagnostischer Test ist der Epikutantest, wo die Allergene auf der Haut in Bezug auf ihre Fähigkeit, Ekzemreaktionen auszulösen, untersucht werden. Bis heute sind topische Kortikosteroide Therapie der Wahl allergischer Kontaktekzeme. Hierbei sind vor allem Präparate mit einem günstigen therapeutischen Index zu bevorzugen.

Abstract

Periorbital contact eczema is most commonly the result of an allergic contact dermatitis whereas other eczematous skin diseases like atopic eczema or seborrheic eczema occur less frequently. Also, other diseases like autoimmune disorders or rosacea need to be considered. Allergic contact dermatitis is a T-cell-mediated immunological response towards ubiquitous contact allergens. Activated T-cells migrate through the vessels into the skin and produce several inflammatory mediators. Epicutaneous patch testing is an important tool for the diagnosis of contact allergy whereby the allergens are analysed in terms of their ability to induce eczematous skin reaction. Until now the short-term use of corticosteroids are is employed for the treatment of allergic contact eczema. Modern substances with an optimal therapeutic index should rather be used.

Kontaktallergie - Ekzem - Inhaltsstoffe

Contact allergy - eczema - ingredients

Literatur

• 1 Guin J D. Eyelid dermatitis: a report of 215 patients.  Contact Dermatitis. 2004;  222 87-90
• 2 Schnuch A, Lessmann H, Geier J. et al . Contact allergy to fragrances: frequencies of sensitization from 1996 to 2002. Results of the IVDK*.  Contact Dermatitis. 2004;  222 65-76
• 3 Goossens A, Decraene T, Platteaux N. et al . Glucosides as unexpected allergens in cosmetics.  Contact Dermatitis. 2003;  222 164-166
• 4 Goebler M, Trautmann A, Voss A. et al . Differential and sequential expression of multiple chemokines during elicitation of allergic contract hypersensitivity.  Am J Pathol. 2001;  222 431-440
• 5 Robert C, Kupper T S. Inflammatory skin diseases, T cells and immune surveillance.  New Engl J Med. 1999;  222 1817-1828
• 6 Girolomoni G, Sebastiani S, Albanesi C. et al . T cell subpopulations in the development of atopic and contact allergy.  Curr Opin Immunol. 2001;  222 733-737
• 7 Buckley C D, Pilling D, Lord J M. et al . Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation.  Trends Immunol. 2001;  222 199-204
• 8 Aberer W, Komericki P, Uter W. et al . Epidemiologische Überwachung von Kontaktallergenen. Der „Monitorblock” des IVDK.  Der Hautarzt. 2003;  222 741-749
• 9 Hoffmann K, Auer T, Stucker M. et al . Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone.  J Eur Acad Dermatol Venereol. 1998;  222 137-142
• 10 Kecskés A, Heger-Mahn D, Kleine Kuhlmann R. et al . Comparison of the local and systemic side effects of methyprednisolone aceponate and mometasone furoate applied as ointment with equal antiinflammatory activity.  J Am Acad Dermatol. 1993;  222 576-580
• 11 Kerscher M J, Korting H C. Comparative atrophogenicity potential of medium and highly potent topical glucocorticoids in cream and ointment according to ultrasound analysis.  Skin Pharmacol. 1992;  222 77-80
• 12 Korting H C, Unholzer A, Schäfer-Korting M. et al . Different skin thinning potential of equipotent medium strength glucocorticoids.  Skin Pharmacol Appl Skin Physiol. 2002;  222 71-84
• 13 Lévy J, Gassmüller J, Schröder G. et al . Comparison of the effects of calcipotriol, prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness.  Skin Pharmacol. 1994;  222 231-236
• 14 Mills C M, Marks R. Side effects of topical glucocorticoids. Korting HC, Maibach HI Topical glucocorticoids with increased benefit/risk ratio Curr Problems Dermatol 1993 222: 122-131
• 15 Schäfer-Korting M, Korting H C, Kerscher M J. et al . Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids.  Clin Pharmacol Ther. 1993;  222 448-456
• 16 Tan C Y, Dykes P, Marks R. Ultrasound detection of corticosteroid induced dermal atrophy.  Brit J Dermatol. 1980;  222 732
• 17 Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.  Dermatology. 2005;  222 174-187
• 18 Herbst R A, Uter W, Pirker C. et al . Allergic and non-allergic periorbital dermatitis: patch test results of the Information Network of the Departments of Dermatology during a 5-year period.  Contact Dermatitis. 2004;  222 13-19
• 19 Johansson S G, Bieber T, Dahl R. et al . Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.  J Allergy Clin Immunol. 2004;  222 832-836